Clinical significance of endothelin-1 and angiotensin-2 levels in patients with post-COVID syndrome according to the timing of rehabilitation therapy
- 30 March 2026
- journal article
- Published by Far Eastern Scientific Center Of Physiology and Pathology of Respiration in Bulletin physiology and pathology of respiration
- No. 99
Abstract
Introduction. Post-COVID syndrome (PCS) leads to multiorgan dysfunction, the primary pathophysiological basis of which is considered to be endothelial dysfunction – a state of imbalance among vasoactive and angiogenic mediators. Aim. To evaluate the clinical relevance of endothelin-1 (EDN1) and angiotensin-2 (ANG-2) levels in PCS patients in relation to the timing of enrollment in rehabilitation treatment. Materials and methods. The study included 190 patients diagnosed with PCS and 30 healthy controls with no prior history of COVID-19. Assessments encompassed clinical, functional, and laboratory evaluations, including enzyme-linked immunosorbent assay (ELISA) for serum levels of ANG-2, EDN1, bactericidal/permeability-increasing protein (BPI), and C-reactive protein (CRP). Pulmonary function was assessed by spirometry. Physical performance was measured using the 6-minute step test (6MST), dyspnea severity via the Baseline Dyspnea Index (BDI). Fatigue was assessed using the Fatigue Assessment Scale (FAS), and health-related quality of life by the SF-36 questionnaire. Results. Patients were stratified into four groups based on PCS duration: Group I (24 months). Cardiovascular comorbidities predominated in Groups I and II, whereas bronchial asthma and chronic bronchitis were more common in Groups III and IV. Notably, 11.5 % of patients developed respiratory diseases de novo after COVID-19. ANG-2 levels were elevated across all PCS groups compared to controls. EDN1 concentrations were highest in Group I (52.3 [33.3; 62.5] pg/mL) versus controls (44.4 [39.81; 47.22] pg/mL) and showed a progressive decline with longer PCS duration: Group II – 39.4 [26.4; 50.0] pg/mL; Group III – 23.2 [16.0; 40.7] pg/mL; Group IV – 18.7 [16.5; 21.7] pg/mL. FAS and SF-36 scores revealed persistent chronic fatigue and reduced quality of life – both physical and mental – among PCS patients. Conclusion. For up to two years following acute COVID-19, patients exhibit signs of unresolved low-grade inflammation and impaired endothelial vasomotor function, which underlie persistent PCS symptoms, including chronic fatigue and diminished quality of life.Keywords
This publication has 16 references indexed in Scilit:
- Long COVID and older peopleThe Lancet Healthy Longevity, 2022
- Physical, cognitive, and mental health impacts of COVID-19 after hospitalisation (PHOSP-COVID): a UK multicentre, prospective cohort studyThe Lancet Respiratory Medicine, 2021
- Persistent symptoms 3 months after a SARS-CoV-2 infection: the post-COVID-19 syndrome?ERJ Open Research, 2020
- COVID-19 is, in the end, an endothelial diseaseEuropean Heart Journal, 2020
- The role of renin-angiotensin system and angiotensin-converting enzyme 2 (ACE2) in the development and course of viral infection COVID-19 in patients with diabetes mellitusDiabetes mellitus, 2020
- Renin–Angiotensin–Aldosterone System Inhibitors in Patients with Covid-19New England Journal of Medicine, 2020
- Pathogenesis of COVID-19 from a cell biology perspectiveEuropean Respiratory Journal, 2020
- Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptorNature, 2020
- Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic targetIntensive Care Medicine, 2020
- ATS Statement: Guidelines for the Six-Minute Walk TestAmerican Journal of Respiratory and Critical Care Medicine, 2002